A recent study examined the risk of clinically relevant bleeding in patients prescribed both DAAs and DOACs. They found a low incidence of bleeding which was not statistically different to historic controls of liver patients on DOACs alone. We have revised our summaries to reflect these new data. Interactions between daclatasvir, elbasvir/grazoprevir, glecaprevir/pibrentasvir, ledipasvir/sofosbuvir, sofosbuvir/velpatasvir, and sofosbuvir/velpatasvir/voxilaprevir and apixaban are now all YELLOW (potential weak interaction).
Evidence from the study has been added to the text of these interactions, and those with edoxaban and rivaroxaban where applicable. Interactions between DAAs and edoxaban and rivaroxaban remain AMBER (potential interaction). This is due to the additive effect of renal impairment with rivaroxaban, and the small numbers of patients on edoxaban included in the paper.
Safe co-administration of direct-acting antivirals and direct oral anticoagulants among patients with hepatitis C virus infection: An international multicenter retrospective cohort study. McDaniel K, Utz AE, Akbashev M et al. J Viral Hepat, 2022; doi: 10.1111/jvh.13750. Online ahead of print.
